Table 1.
Descriptive analysis.
| n = 190 | |
|---|---|
| Median (IQR) age, years | 42 (31–52) |
| Origin, n (%) | |
| Caucasian | 155 (81.6) |
| African | 10 (5.3) |
| East Europe | 21 (11) |
| Asia | 1 (0.5) |
| Other | 3 (1.6) |
| Risk factors, n (%) | |
| Sexual | 170 (89.5) |
| Injecting drug users | 20 (10.5) |
| Median (IQR) duration of cART, days | 1405 (976–2219) |
| Median (IQR) follow-up, days | 1574 (1024–2436) |
| cART, n (%) | |
| 2NRTI + PI | 84 (44.2) |
| 2NRTI + nnrti | 53 (27.9) |
| 2NRTI + INI | 45 (23.7) |
| Other | 8 (4.2) |
| HBV serology, n (%) | |
| Negative | 77 (40) |
| HBcAb positive | 70 (37) |
| HBcAb | 28 (40) |
| HBcAb+ /HBsAb + | 42 (60) |
| HBV vaccination | 43 (23) |
| HCV antibody positivity, n (%) | 9 (4.8) |
| Median (IQR) CD4 cell count at baseline, cells/mmc | 237 (102–419) |
| Median (IQR) nadir) CD4 cell count | 209 (85–357) |
| CD4/CD8 T lymphocyte ratio < 0.45 at baseline, n (%) | 117 (61.6) |
| Median (IQR) HIV-RNA at baseline, cp/mL | 84,932 (34,314–292,310) |
| Mean (SD) log HIV-RNA at baseline, cp/mL, | 4.9 (0.7) |
| Undetectability after 6 months of cART | 146 (76.8) |
| Median (IQR) undetectability, months | 5 (3–6) |
| AIDS-related event, n (%) | 48 (25.3) |
| Non-AIDS related event, n (%) | 75 (39.5) |
| VF, n (%) | 26 (13.7) |
| VB, n (%) | 82 (43.2) |
VB = viral blip, single detection of HIV-RNA > 50 cp/mL; VF = viral failure, two consecutive HIV-RNA ≥ 50 cp/mL or one > 1000 cp/mL with consequent change of cART.
cART = combined antiretroviral therapy; NRTI = nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI = nonnucleoside reverse-transcriptase inhibitors; PI = protease inhibitors; undetectability = HIV-RNA < 50 copies/mL.
AIDS-related events = the occurrence of any opportunistic infections or malignancy according to the World Health Organization (ref. 20); non-AIDS-related events = comorbidities such as hypertension, diabetes and lipidic disorders, bone disorders (osteopenia, osteoporosis), renal impairment and non-AIDS-related neoplastic pathologies.